0001171843-22-007376.txt : 20221110 0001171843-22-007376.hdr.sgml : 20221110 20221110163157 ACCESSION NUMBER: 0001171843-22-007376 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221110 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221110 DATE AS OF CHANGE: 20221110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Atreca, Inc. CENTRAL INDEX KEY: 0001532346 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273723255 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38935 FILM NUMBER: 221377830 BUSINESS ADDRESS: STREET 1: 835 INDUSTRIAL ROAD, STREET 2: SUITE 400 CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 650-595-2595 MAIL ADDRESS: STREET 1: 835 INDUSTRIAL ROAD, STREET 2: SUITE 400 CITY: SAN CARLOS STATE: CA ZIP: 94070 8-K 1 f8k_111022.htm FORM 8-K Form 8-K
0001532346 False 0001532346 2022-11-10 2022-11-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  November 10, 2022

_______________________________

Atreca, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware001-3893527-3723255
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

835 Industrial Rd., Suite 400

San Carlos, California 94070

(Address of Principal Executive Offices) (Zip Code)

(650) 595-2595

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per shareBCELThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 
 
Item 2.02. Results of Operations and Financial Condition.

On November 10, 2022, Atreca, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended September 30, 2022 and recent corporate developments. A copy of such press release is furnished hereto as Exhibit 99.1. 

The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be deemed incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, except as expressly set forth by reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number Exhibit Description
     
99.1 Press Release titled "Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update," dated November 10, 2022, furnished herewith
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 Atreca, Inc.
   
  
Date: November 10, 2022By: /s/ Herbert Cross        
  Herbert Cross
  Chief Financial Officer
  

 

EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update

SAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- SAN CARLOS, Calif., November 10, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2022 and provided an overview of recent developments.

"The third quarter was a productive period, as we continue to enroll patients in the Phase 1b trial of ATRC-101,” said John Orwin, Chief Executive Officer of Atreca. “We remain encouraged by the association we see between clinical activity and target expression, the durability of the clinical activity observed and the tolerability demonstrated in the study. We are making progress toward accelerating enrollment and are now planning to present data in early 2023, once we’ve treated enough participants to provide a meaningful update.”

“An NHP toxicity study to evaluate ATRC-301, an ADC candidate in our anti-EphA2 program, revealed safety signals, including bleeding, and as a result, we are discontinuing the development of ATRC-301; however, we continue to evaluate our anti-EphA2 antibodies in multiple weaponized formats,” said Stephen Gould, Ph.D., Chief Scientific Officer of Atreca. “While this will delay the timing of our next IND in oncology, our preclinical pipeline is otherwise progressing well, and in early 2023 we expect to provide updates on both an ADC targeting a novel tumor glycan and a bispecific T-cell engager targeting another RNA-binding protein.”

“In addition, the Bill & Melinda Gates Medical Research Institute continues to advance MAM01/ATRC-501, an antibody clinical candidate generated by the Atreca platform that is in development for the prevention of malaria, for which they expect to file an IND early next year,” said John Orwin.

Recent Developments and Highlights

Atreca continued enrolling patients in its ongoing Phase 1b study of ATRC-101 based on ATRC-101 target expression in archival or newly obtained biopsies. To-date, 67 participants have been enrolled across the monotherapy and pembrolizumab combination cohorts of the study. The Company has taken steps to accelerate enrollment in the trial, including initiating additional trial sites and streamlining enrollment criteria. Atreca now expects to present updated monotherapy and combination data from the trial in the first quarter of 2023.

An non-human primate (NHP) toxicity study to evaluate ATRC-301, an antibody drug conjugate (ADC) candidate in our anti-EphA2 program, revealed safety signals, including bleeding, and as a result, Atreca is discontinuing the development of ATRC-301. The Company continues to evaluate its anti-EphA2 antibodies in multiple weaponized formats and advance its other lead-stage oncology programs, including APN-497444, an ADC against a novel tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. Atreca is now targeting one additional Investigational New Drug (IND) application per year in oncology beginning in 2024.

A IND for MAM01/ATRC-501, an Atreca-discovered antibody clinical candidate licensed to the Bill & Melinda Gates Medical Research Institute (“Gates MRI”) for the prevention of malaria, is expected to be filed by Gates MRI in the first quarter of 2023, and they expect to commence clinical development by the second half of 2023. Atreca retains commercial rights in the U.S., Europe and parts of Asia, and potential product development opportunities in those regions include prevention of malaria for those traveling to malaria endemic regions.

In October 2022, Atreca announced the presentation of two posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, a trial-in-progress update on the Phase 1b clinical study of ATRC-101, and a poster on the discovery and preclinical development of its novel EphA2-targeted antibodies. Poster sessions began today, November 10th, at 9 a.m. ET.

Third Quarter 2022 Financial Results

  • As of September 30, 2022, cash and cash equivalents and investments totaled $85.7 million.
  • Research and development expenses for the quarter ended September 30, 2022, were $16.0 million, including non-cash share-based compensation expense of $1.9 million.
  • General and administrative expenses for the three months ended September 30, 2022, were $7.2 million, including non-cash share-based compensation expense of $2.0 million.
  • Atreca reported a net loss of $23.1 million, or basic and diluted net loss per share attributable to common stockholders of $0.60, for the three months ended September 30, 2022.

About Atreca, Inc.

Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101, our pipeline of lead-stage oncology programs, and MAM01/ATRC-501, a clinical candidate licensed to the Bill & Melinda Gates Medical Research Institute for the prevention of malaria. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

Forward-Looking Statements

This release contains forward-looking statements regarding our strategy and future plans, including statements regarding enrollment of patients in our Phase 1b clinical trial of ATRC-101, the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof, data read-outs and the timing thereof, including the reporting of updated data from the monotherapy and pembrolizumab combination arms of our Phase 1b clinical trial of ATRC-101, our evaluation of anti-EphA2 antibodies in multiple weaponized formats and advancement of other lead-stage oncology programs, including APN-497444 and APN-346958, the expected timing of INDs, including delays thereof and plans to submit one additional IND per year in oncology beginning in 2024, advancement of MAM01/ATRC-501 by Gates MRI, including plans to commence clinical development by the second half of 2023. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “continue,” “progress,” “accelerate,” “will,” “expect,” “advance,” “target,” and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

Atreca, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)

       
  September 30,   December 31, 
     2022  2021 
  (unaudited)    
ASSETS      
       
Current Assets
Cash and cash equivalents $         20,903  $            94,746 
Investments            64,822                22,287 
Prepaid expenses and other current assets              7,050                  5,337 
Total current assets            92,775              122,370 
Property and equipment, net            39,670                43,015 
Operating lease right-of-use assets            36,481                       -   
Long-term investments                   -                  31,042 
Deposits and other              3,149                  3,630 
Total assets $        172,075  $          200,057 
       
LIABILITIES AND STOCKHOLDERS’ EQUITY
       
Current Liabilities
Accounts payable  $           1,698  $              3,352 
Accrued expenses              9,399                11,555 
Current portion of operating lease liabilities              3,434                       -   
Other current liabilities                   39                  1,992 
Total current liabilities            14,570                16,899 
Deferred rent                   -                  28,229 
Operating lease liabilities, net of current portion            61,252   -  
Total liabilities            75,822                45,128 
       
       
Stockholders’ equity
Common stock                    4                        4 
Additional paid-in capital          532,409              514,794 
Accumulated other comprehensive income (loss)               (581)                  (102)
Accumulated deficit         (435,579)             (359,767)
Total stockholders’ equity             96,253              154,929 
Total liabilities and stockholders’ equity  $        172,075  $          200,057 
       


Atreca, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
(unaudited)

($ amounts in 000's, except per share amounts)            
             
  Three Months Ended
 Nine Months Ended
  September 30,
 September 30,
  2022  2021  2022  2021 
             
Expenses            
Research and development $        16,045  $        18,721  $        53,062  $        56,145 
General and administrative             7,247              8,796            23,930            24,648 
Total expenses           23,292            27,517            76,992            80,793 
Interest and other income (expense)            
Other income                  -                   158                 750                 851 
Interest income                233                  36                 430                 183 
Interest expense                  -                     (1)                  -                     (3)
Loss on disposal of property and equipment                  -                   (34)                   -                   (45)
Loss before Income tax expense          (23,059)          (27,358)           (75,812)          (79,807)
Income tax expense                  -                     -                     -                     (1)
Net loss $       (23,059)  $       (27,358)  $       (75,812)  $       (79,808)
Net loss per share, basic and diluted $          (0.60)  $          (0.74)  $          (1.97)  $          (2.16)
Weighted-average shares used in computing             
net loss per share, basic and diluted     38,720,575      36,918,255      38,434,327      36,884,665 
             

Contacts

Atreca, Inc.
Herb Cross
Chief Financial Officer
info@atreca.com 

Investors:
Alex Gray, 650-779-9251
agray@atreca.com 

Media:
Julia Fuller, 858-692-2001
julia@fordhutmanmedia.com 
Source: Atreca, Inc. 

EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Nov. 10, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 10, 2022
Entity File Number 001-38935
Entity Registrant Name Atreca, Inc.
Entity Central Index Key 0001532346
Entity Tax Identification Number 27-3723255
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 835 Industrial Rd., Suite 400
Entity Address, City or Town San Carlos
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94070
City Area Code 650
Local Phone Number 595-2595
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A Common Stock, $0.0001 par value per share
Trading Symbol BCEL
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 8 f8k_111022_htm.xml IDEA: XBRL DOCUMENT 0001532346 2022-11-10 2022-11-10 iso4217:USD shares iso4217:USD shares 0001532346 false 8-K 2022-11-10 Atreca, Inc. DE 001-38935 27-3723255 835 Industrial Rd., Suite 400 San Carlos CA 94070 650 595-2595 false false false false Class A Common Stock, $0.0001 par value per share BCEL NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_111022.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_111022.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "inline": { "local": [ "f8k_111022.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_111022.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_111022.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001171843-22-007376-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-22-007376-xbrl.zip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end